In May 2023 AngelMed changed its name to Avertix. AngelMed developed the Guardian System, which is an FDA-approved implantable device designed to detect and warn patients of acute thrombotic coronary occlusion.
BIOS Acquisition Corporation, a special purpose acquisition company, then announced that it had entered into a definitive merger agreement with Avertix so it would become a publicly traded company on Nasdaq. The Transaction is expected to close in the second half of 2023. According to the announcement, the combined company, which will be named Avertix Medical, Inc., will have an enterprise value of approximately $195 million.